Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

537
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

616
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
616
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

512
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

743
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
743

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Aerobic Exercise Induces Short-Term Reductions in Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis.

Hypertension (Dallas, Tex. : 1979)·2021
Same author

The Second Wind in McArdle Patients: Fitness Matters.

Frontiers in physiology·2021
Same author

Mortality Risk from Neurodegenerative Disease in Sports Associated with Repetitive Head Impacts: Preliminary Findings from a Systematic Review and Meta-Analysis.

Sports medicine (Auckland, N.Z.)·2021
Same author

Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials.

Ageing research reviews·2021
Same author

Durability and repeatability of professional cyclists during a Grand Tour.

European journal of sport science·2021
Same author

Effects of Combining a Ketogenic Diet with Resistance Training on Body Composition, Strength, and Mechanical Power in Trained Individuals: A Narrative Review.

Nutrients·2021
Same journal

Hyocholic acids: Third bile acids for neonatal health.

Trends in molecular medicine·2026
Same journal

Clonal hematopoiesis in Alzheimer's brain: Protective, pathogenic, and context-dependent?

Trends in molecular medicine·2026
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K

'Mitotherapy' for Heart Failure.

Fabian Sanchis-Gomar1, Giuseppe Lippi2, Alejandro Lucia3

  • 1Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain.

Trends in Molecular Medicine
|March 12, 2016
PubMed
Summary
This summary is machine-generated.

Mitochondrial dynamics, particularly OPA1-mediated fusion and OMA1/YME1L proteases, are crucial in cardiovascular disease. These factors represent promising therapeutic targets for mitigating heart failure progression.

Keywords:
agingheartpathway

More Related Videos

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Related Experiment Videos

Last Updated: Mar 24, 2026

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Area of Science:

  • Cardiovascular Disease Research
  • Mitochondrial Biology
  • Molecular Medicine

Background:

  • Mitochondrial dynamics play a critical role in cellular health and are increasingly implicated in cardiovascular disease.
  • Dysfunctional mitochondrial dynamics are a hallmark of heart failure, necessitating investigation into underlying mechanisms.

Purpose of the Study:

  • To explore the significance of mitochondrial dynamics and their mediators in the context of cardiovascular disease.
  • To identify OPA1 (a GTPase regulating mitochondrial fusion) and mitoproteases (OMA1, YME1L) as potential therapeutic targets for heart failure.

Main Methods:

  • Review of recent research on mitochondrial dynamics in cardiovascular disease.
  • Focus on the roles of OPA1, OMA1, and YME1L in mitochondrial fusion and proteolysis.
  • Analysis of their implications as therapeutic targets.

Main Results:

  • Abnormalities in mitochondrial dynamics are strongly associated with cardiovascular disease.
  • OPA1, a key mediator of mitochondrial fusion, is highlighted for its role.
  • Mitoproteases OMA1 and YME1L are identified as critical regulators in this process.

Conclusions:

  • Mitochondrial dynamics, involving OPA1, OMA1, and YME1L, are central to cardiovascular pathophysiology.
  • Targeting these molecular mediators offers a promising therapeutic strategy for combating heart failure.